Sparks - Oryzon Genomics

Oryzon Genomics has received four decisions to grant for vafidemstat patent applications in South Korea, the Philippines, New Zealand and Mexico, further expanding its IP portfolio across psychiatric and neurodevelopmental conditions. The South Korean and Philippine allowances cover non-aggressive symptoms of borderline personality disorder (BPD), complementing existing protection relating to aggression, while the New Zealand allowance covers aggression and social withdrawal. The Mexican allowance extends protection to certain non-aggressive symptoms of autism spectrum disorder (ASD), broadening vafidemstat’s potential therapeutic coverage.

The BPD patents in South Korea and the Philippines and the ASD patent in Mexico are expected to remain in force until at least 2040, while the New Zealand patent covering aggression and social withdrawal is expected to extend until at least 2038; corresponding US patent protection for BPD extends to at least 2043. These developments strengthen the IP position of vafidemstat as Oryzon prepares a Phase III trial targeting aggression in BPD and progresses its Phase IIb EVOLUTION study in schizophrenia.

This latest news also follows the recent authorisation of the Phase II HOPE-2 study in Phelan-McDermid syndrome, supporting Oryzon’s expansion into genetically defined patient populations. While the decisions remain subject to formal patent grants and do not provide new clinical efficacy evidence, the expanded IP coverage could support future commercialisation and partnering opportunities, subject to successful clinical development and regulatory approval.